Insider Transactions in Q2 2022 at Keros Therapeutics, Inc. (KROS)
Insider Transaction List (Q2 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,400
+9.0%
|
$0
$0.3 P/Share
|
|
Jun 09
2022
|
Jasbir Seehra CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.97%
|
$0
$0.3 P/Share
|
|
May 11
2022
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,300
-1.18%
|
$227,900
$43.35 P/Share
|
|
May 11
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+5.5%
|
$0
$0.3 P/Share
|
|
Apr 11
2022
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,300
-1.49%
|
$328,600
$62.84 P/Share
|
|
Apr 11
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,300
+5.5%
|
$0
$0.3 P/Share
|
|
Apr 06
2022
|
Christopher Rovaldi Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
1,728
-100.0%
|
$112,320
$65.0 P/Share
|
|
Apr 06
2022
|
Christopher Rovaldi Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,728
+50.0%
|
$27,648
$16.0 P/Share
|
|
Apr 04
2022
|
Jennifer Lachey Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,950
-8.49%
|
$477,000
$60.0 P/Share
|
|
Apr 04
2022
|
Jennifer Lachey Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,950
+7.82%
|
$0
$0.3 P/Share
|
|
Apr 01
2022
|
Christopher Rovaldi Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
864
-45.57%
|
$48,384
$56.85 P/Share
|
|
Apr 01
2022
|
Christopher Rovaldi Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
864
+50.0%
|
$13,824
$16.0 P/Share
|